Consun Pharmaceutical (HKG:1681) unit Guangzhou Consun Pharmaceutical agreed to invest 191.4 million yuan in Shanghai Huamao Pharmaceutical for a 30% stake, according to a Monday Hong Kong bourse filing.
The investment will be made through the purchase of existing equity interest and a capital increase in cash.
Shanghai Huamao Pharmaceutical is a biotechnology and pharmaceutical company and acts as a supplier of Consun Pharmaceutical.
The purchase will facilitate market expansion, vertical integration, supply strengthening, and R&D resource sharing for the firm among other benefits.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments